Testing effectiveness (Phase 2)Study completedNCT06272487
What this trial is testing
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3)
Who this might be right for
High Cardiovascular RiskHypertension
Alnylam Pharmaceuticals 375